Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders -October 25, 2023 at 08:00 am EDT
- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 - ORX750 advancing in IND-enabling studies; Clinical proof...
Source: marketscreener.com